Abstract
37MO Niraparib maintenance therapy in patients with newly diagnosed advanced ovarian cancer: A post hoc analysis on efficacy by surgical timing and residual disease status in the phase III PRIME trial
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have